An independent intelligence board aggregating credible research, preprints, clinical findings, biohacking experiments, and community discussions on therapeutic peptides, longevity science, and evidence-based anti-aging. Stories are scored for relevance, credibility, novelty, momentum, and practicality so the most important findings surface first.
A company called CoreAgeRx has announced new “preventive longevity” programs that use very small doses (microdosing) of semaglutide and tirzepatide, plus a therapy called sermorelin. In plain terms, they’re offering treatments aimed at slowing aging or preventing age-related decline using medicines some people already know from weight and diabetes care, along with a growth-hormone–related peptide. Semaglutide is the active ingredient in drugs like Ozempic and Wegovy. It copies a natural gut hormone that helps control appetite and slows how quickly the stomach empties, which can reduce how much people eat and help with weight loss. Tirzepatide is a newer drug that acts on two appetite and blood sugar–related pathways at once; it has been used to treat diabetes and has shown strong weight-loss effects. Sermorelin is different: it’s a short peptide that stimulates the body’s own release of growth hormone, and it’s sometimes used in clinics to try to improve energy, muscle mass, or sleep, though evidence is mixed. The announcement is a company launch, not a scientific paper. It says the protocols will use “microdosing” of the drugs plus sermorelin, but the snippet doesn’t give details like how many people were treated, what exact doses will be used, or any trial results. Because this is a business press release, there’s no clear evidence presented here that these protocols produce the promised longevity benefits. We do know from separate, published research that full-dose semaglutide and tirzepatide can cause significant weight loss and improve metabolic health in many people; evidence that microdoses or sermorelin meaningfully extend lifespan in humans is limited or lacking. For someone curious about aging and health, this matters because clinics are increasingly marketing medical treatments to slow aging, and existing drugs for weight and diabetes are being repurposed in new ways. If you’re interested in preventive health, this could be an option to discuss with a doctor—especially if you have weight or blood-sugar concerns—but it’s important to treat company claims cautiously until clinical trials back them up. People already using or considering GLP-1 drugs (the class that includes semaglutide) should know more clinics now offer off-label regimens and combination therapies. There are important caveats and risks. Semaglutide and tirzepatide have side effects like nausea, diarrhea, and potential effects on the gallbladder and pancreas; long-term effects of low-dose or mixed regimens aren’t well studied. Sermorelin affects growth-hormone pathways, which can have their own risks and are not proven to extend healthy lifespan. These treatments require medical supervision, and they may not be safe for people with certain conditions such as pregnancy, personal or family history of certain cancers, or pancreatitis. Also, a company announcement is not the same as regulatory approval for anti-aging use. Bottom line: CoreAgeRx is pitching a clinic program combining low doses of known metabolic drugs and a growth-hormone stimulator as “preventive longevity” care, but the claim lacks published evidence here—talk to a qualified clinician and be cautious about unproven anti-aging promises.
Source: Media Decision